Physician profile
Randall J Burt
NPI 1518965219
$10,887.43
in general payments reported to CMS, 2019-2025
42 companies · $6,379 in 2025
The $6,379 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $106 · 2021: $464 · 2022: $798 · 2023: $551 · 2024: $2,251 · 2025: $6,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,800 · Food and Beverage: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,800.00 |
| Food and Beverage | $1,379.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $7,800.00 | 2024-2025 | Bovine Collagen |
| Pfizer INC. | $424.16 | 2019-2024 | |
| Abbvie INC. | $335.56 | 2019-2023 | Lo Loestrin Fe |
| Exeltis, USA INC. | $278.55 | 2019-2024 | Slynd |
| Mayne Pharma Commercial LLC | $271.73 | 2022-2024 | |
| Hologic Sales and Service, LLC | $202.11 | 2020-2025 | Aptima, Novasure, Myosure Tissue Removal Device |
| Astellas Pharma US INC | $185.71 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $141.43 | 2021-2025 | |
| Aspira Women'S Health INC | $124.95 | 2022 | |
| Sumitomo Pharma America, INC. | $120.14 | 2023-2025 | Myfembree |
| Daiichi Sankyo INC. | $85.55 | 2019-2022 | |
| Millicent US INC | $70.35 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Avion Pharmaceuticals | $66.49 | 2019-2021 | |
| Myovant Sciences INC. | $63.98 | 2022 | |
| Organon LLC | $61.16 | 2021-2024 | Nexplanon |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Burt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.